Alps Advisors Inc. raised its stake in shares of Emergent Biosolutions, Inc. (NYSE:EBS) by 42.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 52,811 shares of the biopharmaceutical company’s stock after buying an additional 15,844 shares during the quarter. Alps Advisors Inc. owned about 0.13% of Emergent Biosolutions worth $2,136,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in EBS. Riverhead Capital Management LLC raised its stake in Emergent Biosolutions by 102.8% during the second quarter. Riverhead Capital Management LLC now owns 3,042 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 1,542 shares during the last quarter. Ameritas Investment Partners Inc. raised its stake in Emergent Biosolutions by 23.2% during the second quarter. Ameritas Investment Partners Inc. now owns 3,118 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 587 shares during the last quarter. Creative Planning raised its stake in Emergent Biosolutions by 1.2% during the second quarter. Creative Planning now owns 4,555 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 55 shares during the last quarter. First Quadrant L P CA purchased a new position in Emergent Biosolutions during the third quarter valued at $157,000. Finally, Meeder Asset Management Inc. raised its stake in Emergent Biosolutions by 94.7% during the third quarter. Meeder Asset Management Inc. now owns 4,732 shares of the biopharmaceutical company’s stock valued at $191,000 after buying an additional 2,302 shares during the last quarter. Institutional investors and hedge funds own 85.97% of the company’s stock.

EBS has been the subject of a number of recent research reports. Zacks Investment Research cut Emergent Biosolutions from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. BidaskClub cut Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Finally, Wells Fargo & Company reiterated an “outperform” rating and set a $43.00 price objective (up previously from $41.00) on shares of Emergent Biosolutions in a research note on Saturday, September 30th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $45.00.

Emergent Biosolutions, Inc. (NYSE EBS) traded up $0.29 during mid-day trading on Monday, hitting $40.86. The stock had a trading volume of 247,000 shares, compared to its average volume of 324,467. Emergent Biosolutions, Inc. has a 52-week low of $25.96 and a 52-week high of $44.86. The company has a quick ratio of 6.46, a current ratio of 7.37 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $1,691.42, a PE ratio of 21.62, a P/E/G ratio of 1.13 and a beta of 1.22.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.32. Emergent Biosolutions had a return on equity of 15.20% and a net margin of 15.60%. The firm had revenue of $149.43 million during the quarter, compared to analysts’ expectations of $124.55 million. During the same quarter in the previous year, the business earned $0.56 earnings per share. The company’s revenue was up 4.6% on a year-over-year basis. analysts expect that Emergent Biosolutions, Inc. will post 1.64 EPS for the current year.

In other news, Director Ronald Richard sold 1,266 shares of the business’s stock in a transaction on Wednesday, September 27th. The stock was sold at an average price of $40.00, for a total value of $50,640.00. Following the completion of the transaction, the director now owns 24,676 shares in the company, valued at $987,040. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director George A. Joulwan sold 14,251 shares of the business’s stock in a transaction on Tuesday, November 7th. The stock was sold at an average price of $41.24, for a total value of $587,711.24. Following the completion of the transaction, the director now owns 34,323 shares of the company’s stock, valued at approximately $1,415,480.52. The disclosure for this sale can be found here. Insiders sold 225,986 shares of company stock valued at $8,929,278 in the last 90 days. Company insiders own 16.50% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/11/13/alps-advisors-inc-buys-15844-shares-of-emergent-biosolutions-inc-ebs.html.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions, Inc. (NYSE:EBS).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Stock Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related stocks with our FREE daily email newsletter.